| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 15 May 2026 | 7 May 2026 |
| Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended 31st March, 2026 We are hereby submitting audited standalone and consolidated financial results for the quarter ended 31st March, 2026 We are hereby submitting audited standalone and consolidated financial results of the Company for the quarter ended 31st March, 2026 (As Per BSE Annoncement Dated on:15.05.2026) | ||
| Board Meeting | 25 Mar 2026 | 25 Mar 2026 |
| Board approved the allotment of bonus equity shares in the ratio of 1:1 | ||
| Board Meeting | 11 Feb 2026 | 4 Feb 2026 |
| Quarterly Results & Increase in Authorised Capital & Bonus issue Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve unaudited quarterly financial results for the quarter ended 31st December, 2025, Bonus Issue, Increase Authorised Capital, Convene EGM, finalise record date Please find attached unaudited standalone and consolidated financial results for the year ended 31st December 2026 (As Per BSE Announcement Dated on 11.02.2026) | ||
| Board Meeting | 13 Nov 2025 | 8 Nov 2025 |
| Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve Consideration and Approval of Unaudited Financial Statement of the Company for the quarter ended 30th September 2025 We are hereby submitting the unaudited financial results for the quarter ended 30th September, 2025 (As Per BSE Announcement Dated on 13.11.2025) | ||
| Board Meeting | 26 Aug 2025 | 25 Aug 2025 |
| Outcome of board meeting for allotment of right issue shares Postponement of credit of right issue and listing of shares (As Per BSE Announcement Dated on: 25/08/2025) | ||
| Board Meeting | 13 Aug 2025 | 7 Aug 2025 |
| Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June 2025 Outcome of Board meeting is enclosed herewith (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 12 Jul 2025 | 12 Jul 2025 |
| Board meeting to approve issue period and letter of offer Submission of Corrigendum of Outcome of Board meeting held on July 12, 2025 | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
